Rituximab is effective in controlling CS without any cardiac adverse effects. ICD helps prevent SCD in patients with advanced conduction defects. TNF-α inhibitors have a proven record of reducing disease activity and improving outcomes. Cardiac MRI and FDG-PET scans are essential for monitoring CS progression and treatment response. This evidence concerns the gene TNF and Schnyder corneal dystrophy.